PT  - JOURNAL ARTICLE
AU  - Sanz-Leon, Paula
AU  - Stevenson, Nathan J.
AU  - Stuart, Robyn M.
AU  - Abeysuriya, Romesh G.
AU  - Pang, James C.
AU  - Lambert, Stephen B.
AU  - Kerr, Cliff C.
AU  - Roberts, James A.
TI  - Susceptibility of zero community transmission regimes to new variants of SARS-CoV-2: a modelling study of Queensland
AID  - 10.1101/2021.06.08.21258599
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.08.21258599
4099  - http://medrxiv.org/content/early/2021/07/08/2021.06.08.21258599.short
4100  - http://medrxiv.org/content/early/2021/07/08/2021.06.08.21258599.full
AB  - Objectives To assess the risk of sustained community transmission of SARS-CoV-2/COVID-19 in Queensland (Australia) in the presence of high-transmission variants of the virus.Design We used an agent-based model Covasim and the demographics, policies, and interventions implemented in the state. Using the calibrated model, we simulated possible epidemic trajectories that could eventuate due to leakage of infected cases with high-transmission variants, during a period of zero community transmission.Setting Model calibration covered the first-wave period from early March 2020 to May 2020. Predicted epidemic trajectories were simulated from early February 2021 to late March 2021.Participants None (simulation study).Main outcomes A calibrated model of COVID-19 epidemiology in Queensland; the conditions that could lead to an outbreak; and how likely that situation is to occur given our current levels of testing and vaccination coverage.Results Simulations showed that one infected agent with the ancestral (A.2.2) variant has a 14% chance of crossing a threshold of sustained community transmission (i.e., > 5 infections per day, more than 3 days in a row), assuming no change in the prevailing preventative and counteracting policies. However, one agent carrying a more infectious variant (e.g., B.1.1.7) has a 43% chance of crossing the same threshold; a threefold increase. Doubling the average number of daily tests results in a decrease of this probability from 43% to 33%. Similarly, achieving a coverage of 70% with a vaccine with 70% efficacy would decrease the probability of SCT from a single seed of B.1.1.7 from 43% to 20%, on par with the ancestral strain in a naive population.Conclusions The introduction of even a small number of people infected with high-transmission variants dramatically increases the probability of sustained community transmission in Queensland.The known The COVID-19 B.1.1.7 (Alpha) variant is 40%-90% more transmissible than the ancestral strain. However, the probabilities of developing sustained community transmission in Queensland, a zero community transmission setting, are unknown.The new Using an agent-based model, with the levels of testing observed in Queensland during February–March 2021, we found that as few as 3 agents infected with a highly-transmissible variant lead to an 80% chance of developing sustained community transmission.The implications Until high vaccine coverage is achieved, a swift implementation of policies and interventions, together with high adherence rates, will be required to minimise the probability of sustained community transmission from high transmission variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by QIMR Berghofer Medical Research Institute through generous philanthropic donations and state government funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used statistical aggregated human data, thus does not require the approval of an ethical committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available in a public, open-access repository. https://github.com/brain-modelling-group/covasim-qld-model